



Commercial/Healthcare Exchange Quantity Limit Criteria
Effective: March 8th, 2019

Prior Authorization: Arikayce

Products Affected: Arikayce (amikacin liposome) Inhalation Suspension

Type of Quantity Limit:

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): _____

Limits to be applied:

Coverage will be provided only up to the limits specified below.

Arikayce inhalation suspension: 235.2 mL per 28 days

References:

1. Arikayce [package insert]. Bridgewater, NJ; Inmed; February 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	03/06/2019

Last Res. March 6, 2019